Novartis (NVS) said Sunday that data from a new subgroup analysis of a phase 2 trial evaluating Kisqali, plus endocrine therapy, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer showed reduced risk of recurrence across all efficacy measures.
The company said data from the median follow-up of 44.2 months demonstrated that patients receiving Kisqali saw "consistent reductions" in risk of recurrence, with pre-menopausal and younger patients experiencing greater reductions than post-menopausal patients.
Tolerability also remained consistent as the study saw fewer treatment discontinuations from adverse events among pre-menopausal patients, Novartis added.
The company said data from the trial is set to be presented at Sunday medical meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.